Menu
Poster Presentations
Student
- M 01: A Gap Analysis of Marketers' Approach to Marketing of Pharmaceuticals and the Essential Functions of Marketing in Pharma 3.0
- M 02: Factors Influencing Quality Decision Making in Medicines Development and Regulatory Review
- M 03: Analysis of Postmarket Safety Labeling Changes: Comparison of Expedited Versus Standard NDA Approvals
- M 04: The Key Issues of the Trial Subjects’ Protection During First in Human and Bioequivalence Studies
- M 06: Analysis of Off-Patent Pharmaceutical Price Increases: 2013-2016
- M 07: Synergetic Prevention of Sudden Death by ACEI, Statin and Gliflozin in Type 2 Diabetes: A Simulation Study
- M 08: Formulary Processes of Major Countries
- M 09: Evaluation and Characterization of Health Economics and Outcomes Research in SAARC Nations
- M 10: Factors That Affect Market Share of Biosimilars Against Reference Biologics
- M 11: Best Practices for the Design and Dissemination of Patient Medication Information: A Systematic Review
- M 12: Impact of Smartphone Use in Health Care by Providing Smartphones to Patients: A Systematic Review
- M 14: Pediatric Opioid Exposures and Poisonings: Prevalence and Characteristics
- M 15: Identifying Symptoms and Functional Impact Reported by Persons with Multiple Sclerosis: A Qualitative Literature Review
- M 16: Direct-to-Consumer Television Marketing of Oncology Products in the US
- M 17: Unique Pharmaceutical Market and Pricing System in Japan: Suggestions to Global Pharma for Effective Market Penetration
- M 19: Adherence to Guideline on Use of Analgesics in Patients with First Myocardial Infarction Event: A Stepped-Care Approach
- M 20: Three Decades Research Advances in Pharmaceutics and Drug Delivery Systems: A Global View of Big Data
- M 21: Benefit-Risk Assessment of HPV Vaccination Program in Japan
- M 22: Trends in Endpoint Selection in Clinical Trials of Advanced Breast Cancer
- M 23: Global Effects of FDA Guidance Requiring Evaluation of Cardiovascular Risk in New Antidiabetic Therapies on Drug Development
- M 24: Evaluation of the Appropriateness of Mupirocin Prescription in the Ambulatory Setting
- M 25: Do Clinical Trials Conducted in India Match its Health Care Needs? An Audit of Two Clinical Trials Registries
- M 26: Do Drugs Interact Together in Cardiovascular Prevention? A Meta-Analysis of Powerful Randomized Controlled Trials
- M 27: Evaluation of Public Awareness and Impact of the Turkish Regulatory and Reimbursement Processes on Patients’ Access to Medicines
Professional
- T 01: Cost Effectiveness Analysis of HLA-B5801 Genotyping in the Treatment of Gout Patients with Chronic Renal Insufficiency
- T 02: Practical Aspects of Developing, Implementing and Using Facilitated Regulatory Pathways (FRPs) in the Emerging Markets
- T 03: Sponsor Attitudes and Behaviors on Patient Recruitment: Insights from Line Management Clinical Operations Personnel
- T 04: Missing ePRO Data: Impacts on Clinical Trial Results
- T 05: Compare the Quality of Case Reports Originating from Social Media with Spontaneous Case Reports by Evaluating Case Attributes
- T 07: Strong Considerations for Self-Reporting Prospective Suicidal Ideation Using the eC-SSRS
- T 08: Cost Drivers of a Hospital Acquired Bacterial Pneumonia and Ventilator Acquired Bacterial Pneumonia (HABP/VABP) Phase III Clinical Trials
- T 09: Albuminuria in Cardiovascular Outcome Trials: Balancing Event and Recruitment Rates
- T 10: Teething Problems of Global Harmonization with Regard to Bioequivalence Assessment: Proton Pump Inhibitors
- T 11: Bridging the Gap: The Need for a Paradigm Shift in Clinical Trial Design to Ensure Continued Patient Access to Medicines
- T 12: Special Safety Considerations for Gene Therapy Products in Global Clinical Development
- T 13: Going Beyond Data Virtualization: Advancing Research with a Transformational Informatics Platform
- T 14: The Conundrum of Fracture Risk in Users of Proton Pump Inhibitors: A Retrospective Analysis
- T 15: Impact of Risk Evaluation Mitigation Strategy on Use of Erythropoiesis-Stimulating Agents
- T 16: Best Practices for Medical Review Process in Clinical Research
- T 17: Mobile CRAs: Transforming Clinical Monitoring Processes through Mobile Technology
- T 18: Comparing the Equivalence of EQ-5D-5L PROM Across Paper and Electronic Modes of Administration
- T 19: Stack, Swarm, Arc: Data Visualizations
- T 20: US Outcomes-Based Drug Pricing: A Fad or the Future?
- T 21: Risk Assessment of Sites Through Risk-Based Monitoring (RBM): Do Your Monitors Agree? A Joint Case Study
- T 22: Comparative Strengths of Public and Commercial Clinical Trials Databases: A Case Study
- T 23: Patient Reported Outcomes: Comparison of Required Data Cleaning Efforts for ePRO Versus Paper
- T 24: Patient Recruitment on Social Media: a Qualitative Analysis of Strategies by Pharmaceutical Companies on Facebook and Twitter
- T 25: Cultural Adaptation of the TOMMORROW Cognitive Battery in Russia, Switzerland, and Italy
- T 26: The Impact of Regulatory Policy on the Development of Clinical Trials in Taiwan
- T 27: So You Want to Influence Stakeholders…Now What? How Outreach Programs can Advance Clinical Research
- T 28: Maximizing Awareness of Post-PharmD Opportunities in Industry Through Targeted National and Regional Recruitment Initiatives
- T 29: Risk of Asthma Attacks is Increased in Association With Nonsteroidal Anti-Inflammatory Drugs Adjusting for Season Effects
- T 30: Identifying TPPs and Establishing CQAs to Support Commercial Product Specifications
- T 31: Comparison of Feature Encoding Methods for Automated Document Classification in Adverse Event Detection
- T 32: Disrupting Clinical Trials in The Cloud
- T 33: Utilization of National Webinars to Reach Students for Educational Opportunities: A Two Year Analysis
- T 34: Signal Analysis of Adverse Drug Reactions: Signal Detection/Evaluation Method Formulation Using Important Risk Visualizer™
- T 35: Bridging Study Evaluation in Taiwan
- T 36: Reduce Training Redundancies to Improve Clinical Trial Efficiency
- T 37: Use of a Mobile Robot to Facilitate Long Distance Professional Development Meetings For Post-Doctoral Fellows
- T 38: Electronic Document Presentation During a Japan PMDA Inspection
- T 39: Bangladesh: A New Frontier for Global Clinical Trials
- T 40: What’s in a Number? Differences in Enrollment Rate Calculation Methodologies for Clinical Trial Planning
- T 41: Enabling Global Regulatory Submission Project and Portfolio Management
- T 42: Talimogene Laherparepvec: Advanced Therapy Medicinal Product (ATMP) – A Distinct Risk Management Plan
- T 43: Evidence for Empirical Power Law Scaling in Adverse Event Profiles
- T 44: Current Japanese Diabetic Mellitus Prevalence and Glucose Clamp Studies for Global Anti-Diabetic Development
- T 45: Evolution of e-System to Support Needs of Agile Pharmaceutical Company: A Case Study of Growing Together
- T 46: Do Environmental Parameters Influence the Prediction of the Placebo Response?
- T 47: True Globalization of the PSMF and Why It's a Useful Tool for Non-EU Pharmaceutical Companies
- T 48: Best Practices for Development or Migration of Patient-Reported Outcome Measures for use on Multiple Data Collection Modes
- T 49: Establishment of Foreign Adverse Event Reporting System in Korea (KAERS-foreign)
- T 50: US Trends in Drug Pricing Policy: Past, Present and Future
- T 51: A Comparison of CDRH Review Times of Original PMA Applications for Products Classified as Combination versus Non-Combination
- T 52: Evaluating the Level of Medical Information Provided for Health Care Professionals on Consumer Care Websites
- T 53: Calling All Patients: Using a Clinical Call Center to Perform Disease Activity Assessments to Support Treating RA to Target
- W 01: Clinical Development in Regulated and Unregulated Markets: Understanding Safety Reporting Requirements
- W 02: End-to-End Change Control: An Integral Approach to Product Changes, Submissions, and Variation Management
- W 04: A Value-Driven Decision Making for Drug Development Strategy
- W 05: Unusual Data Pattern Analysis in a Large Pharmaceutical Company
- W 06: Design of Physicochemical Compatibility Studies for Sterile Injectable Products: Key Lessons from Recent Filings
- W 07: Effectively Evaluating Risk Minimization: Mitigating the Risk of Inadequate Assessments
- W 08: Increasing the Efficiency of Investigator-Initiated Research in China
- W 10: Process and Pitfalls of Preparing Breakthrough Therapy Designation Documents
- W 11: Integral Authoring: A New Paradigm for Data-Driven Structured Authoring of Documents in the Life Sciences Industry
- W 12: Tipping Point Sensitivity Analysis in Continuous Asthma Quality of Life Questionnaire Endpoint
- W 13: Switching Endpoints Based on an Interim Analysis
- W 14: Evaluating REMS Burden: A Comparative Time Analysis of Three Options for REMS Stakeholders to Perform Mandatory REMS Tasks
- W 15: Applications of Expanded Access/Compassionate Use Programs for Evidence Generation
- W 16: An Investigation Into the Distribution of BRCA 1/2 Mutation/Ness Breast and Ovarian Cancer Populations
- W 17: Characteristics That May Help in the Identification of Potentially Confusing Proprietary Drug Names
- W 18: Quality Consistency Assessment for Botanical Medicines using Chromatographic Fingerprint
- W 19: Implementing and Monitoring the Use of Interactive Risk Communications
- W 20: Digital Health Networks as a Change Agent of Public Perceptions for Clinical Trials
- W 21: Utilizing Simulations to Enhance Randomization Methodology Decision Making
- W 22: Best Practices for Pregnancy Outcome Monitoring in the Post Marketing Environment
- W 23: Use of Juvenile Animal Studies to Support Oncology Medicine Development in Children
- W 24: Innovation in Regulatory Science: Development and Validation of an Instrument for Assessing the Quality of Decision Making
- W 25: Industry-Based Pharmacists and Moonlighting: Remaining Current in Clinical Practice
- W 26: Impact of Internal Data Review and Source Data Verification on Overall Data Quality
- W 27: Is the World’s Third Largest Pharmaceutical Market Ready for Patient-Centric Clinical Trials?
- W 28: Development of a Matching Dictionary Between Lay and Corresponding Scientific Terms to Detect Web Reported Adverse Events
- W 29: SC Influence on the Cost of Conducting Clinical Trials and Impact on Pricing of Related Services: Evidence from a Pilot Study
- W 30: Implementing Neurocognitive Testing in Clinical Trials: Facilitating Rater Administration With an iPad-Based App
- W 31: Impact of Biosimilars in Clinical Practice and Clinical Research: Results of Questionnaire- Based Survey
- W 32: Geo-Political Analysis of Phase 3 Clinical Trial Recruitment: Changes in 2015
- W 33: A Comparison of Single-Dose Pharmacokinetics Studies in Subjects with Various Degrees of Renal Impairment
- W 34: Urodynamic Measurement of Urethral Closure Function in Healthy Japanese Women: A Single Dose Study of Duloxetine
- W 35: Comparison of Manual Versus Automated Redaction Techniques for Clinical Submission Documents
- W 36: The Influence of Atipic Antipsychotic Drugs on Vas Deferens in Mice
- W 38: Patient Preference for Electronic Patient Reported Outcomes: Assessment in Patients with Psoriatic Arthritis (PsA)
- W 39: Novel Use of a Medication Event Monitoring System to Track Rescue Medication Use in a Trial of a New Meloxicam Drug Product
- W 41: Engaging Patients with eClinical Technology: Incorporating Patient Preferences into Osteoarthritis Management and Care
- W 42: Adaptive Design in Dose Selection Study of Next-in-Class NNRTI
- W 43: Pooled Continued Access Protocol for Oncology Experimental Therapeutics No Longer in Development
- W 44: Social Listening for a New Product Launch and Beyond: How Does the Conversation Change Over Time?
- W 45: Real-Time Monitoring of the Digital Patient in Clinical Trials
- W 46: Proof of Concept for the Development of Digital Biomarker using Raw Actigraphy Data from a Wrist Wearable Device
- W 47: Testing for Bioequivalence in Higher-Order Crossover Designs: Two-at-a-Time Principle Versus Pooled ANOVA
- W 48: Regulatory Turnaround Makes India an Increasingly Attractive Location for Clinical Research
- W 49: Integrated Solution to Improve Eligibility Fraction and Time Factor in Patient Recruitment for Clinical Trials
- W 51: Predicting Future State and Business Drivers of Safety System Upgrades based on Safety Database Upgrade and Industry Trends
- W 52: Visualizing Patients' ADaM Data via SAS and R